Antibe Therapeutics

Primary market research with U.S. clinicians confirms high unmet need for safer non-opioid medications for acute pain.

$ATE.TO $ATBPF

Read the our latest press release here: https://loom.ly/NA7-tLE

$ATE.TO $ATBPF

Read our latest press release here: https://loom.ly/YY6GvCE

$ATE.TO $ATBPF

Beginning with a commercial focus on post-operative pain, we plan to rapidly expand into other acute areas, including acute musculoskeletal pain, dysmenorrhea, migraine, gout, and dental pain.

$ATE.TO $ATBPF

Positioned as the non-opioid of choice for acute pain, otenaproxesul is headed into its Phase II trial next month – addressing a US $25+ billion market with no novel drugs introduced in 25 years...

$ATE.TO $ATBPF

Read the our latest press release here: antibethera.com/news/antibe-reports-q3-2024-interim-financial-and-operating-results

$ATE.TO $ATBPF

$ATE.TO $ATBPF

The research on hydrogen sulfide's therapeutic potential keeps growing... for the latest on its cardioprotective effects, see this recent paper in Cells: mdpi.com/2073-4409/13/2/158

$ATE.TO $ATBPF

Check out our new Corporate Presentation, including otenaproxesul's remaining path to approval on slide 28... find it at antibethera.com/investors/dashboard

As the opioid crisis drives prescribers, patients, payors and policymakers toward non-addictive alternatives, nonsteroidal anti-inflammatory drugs (NSAIDs) are increasingly employed to treat acute pain. However, today's NSAIDs can cause gastrointestinal ulcers and bleeding, especially at the higher doses often employed in acute indications. Formulated to promote rapid onset of action, otenaproxesul is a non-opioid oral painkiller. Its Phase II trial is set to initiate in calendar Q1 2024, with top-line data expected in Q3 2024. With no novel oral pain drugs introduced since the late 1990s, there is urgent demand for alternatives to opioids to treat post-operative pain, acute musculoskeletal pain, dental pain and a range of other acute pain indications.

Watch as Ankit Bhargava, MD of Allele Capital joins Dan Legault, Chief Executive Officer of Antibe Therapeutics, and Dr. Joe Stauffer, the company's Chief Medical Officer, to discuss the benefits of otenaproxesul's new formulation, dive into Antibe's recently released data and Phase II planning, and explore the future of pain management.

Our lead drug, otenaproxesul, is a non-opioid in clinical development for acute pain... targeting a $25 billion market that's seen no novel compounds introduced in 25 years.

With its Phase II trial set to launch this quarter, our next-generation NSAID aims to offer better GI safety while benefiting from a favorable cardiovascular profile.

To simulate drug effects on the liver, we use DILIsym, a sophisticated software model widely used to predict liver safety, As predicted by DILIsym, our recent clinical PK/PD study showed all envisioned acute pain treatment regimens to be liver-safe.

In light of the strong safety and PK data from otenaproxesul’s recent clinical PK/PD study, Antibe is upgrading the design of the upcoming Phase II trial. We're on track to initiate the trial next quarter with top-line results anticipated in calendar Q3 2024.

As an inflammation mediator, hydrogen sulfide can protect the digestive tract from NSAID-induced damage.

Learn about how gaseous mediators are being utilized in the next generation of anti-inflammatory drugs (co-authored by Antibe's founder Dr. John Wallace) frontiersin.org/articles/10.3389/fphar.2021.657457/full

$ATE.TO $ATBPF

Antibe's lead drug is a non-opioid painkiller targeting a wide range of acute pain indications.

$ATE.TO $ATBPF

A recent article in Barron's (a WSJ publication) speaks eloquently to the market opportunity for novel non-opioid painkillers:

"A nonaddictive pain pill that works as well as an opioid, with none of the same addiction risk and side effects, would be an instant blockbuster."

That's a good summary of otenaproxesul's target product profile.

To read more, click here: barrons.com/articles/vertex-pain-pill-non-opioid-573cae68 (paywalled but the first few lines provide a good overview). To hear Dan Legault, Antibe's CEO, in a recent interview that includes discussion of the Barron's article, click on this link https://cdn.jwplayer.com/previews/CmrZMZl9

$ATE.TO $ATBPF

Read our latest press release here:

antibethera.com/news/antibe-reports-q2-2024-interim-financial-and-operating-results

$ATE.TO $ATBPF

Read our latest press release here:

antibethera.com/news/antibe-reports-pk-results-of-first-clinical-study-of-otenaproxesuls-new-formulation

$ATE.TO $ATBPF

According to the NIH, postoperative pain is experienced by the vast majority of patients who undergo surgical procedures. Control of postoperative pain plays an essential role in facilitating a patient’s recovery to normal function and reduces the incidence of adverse physiologic and psychological effects associated with acute, uncontrolled pain.

$ATE.TO $ATBPF

Read our latest press release here:

antibethera.com/news/antibe-completes-first-clinical-study-of-otenaproxesuls-new-formulation

$ATE.TO $ATBPF